These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9875670)

  • 1. Genetic immunization against neu/erbB2 transgenic breast cancer.
    Amici A; Venanzi FM; Concetti A
    Cancer Immunol Immunother; 1998 Dec; 47(4):183-90. PubMed ID: 9875670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
    Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
    Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
    Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
    Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants.
    Chang SY; Lee KC; Ko SY; Ko HJ; Kang CY
    Int J Cancer; 2004 Aug; 111(1):86-95. PubMed ID: 15185348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice.
    Esserman LJ; Lopez T; Montes R; Bald LN; Fendly BM; Campbell MJ
    Cancer Immunol Immunother; 1999 Feb; 47(6):337-42. PubMed ID: 10203064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity.
    Jacob JB; Kong YC; Nalbantoglu I; Snower DP; Wei WZ
    J Immunol; 2009 May; 182(9):5873-81. PubMed ID: 19380836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA.
    Concetti A; Amici A; Petrelli C; Tibaldi A; Provinciali M; Venanzi FM
    Cancer Immunol Immunother; 1996 Dec; 43(5):307-15. PubMed ID: 9024508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
    Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
    Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span.
    Provinciali M; Barucca A; Orlando F; Pierpaoli E
    Sci Rep; 2017 Jun; 7(1):3078. PubMed ID: 28596550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice.
    Amici A; Smorlesi A; Noce G; Santoni G; Cappelletti P; Capparuccia L; Coppari R; Lucciarini R; Petrelli C; Provinciali M
    Gene Ther; 2000 Apr; 7(8):703-6. PubMed ID: 10800094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine.
    Park JM; Terabe M; Steel JC; Forni G; Sakai Y; Morris JC; Berzofsky JA
    Cancer Res; 2008 Mar; 68(6):1979-87. PubMed ID: 18339880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
    Saha A; Chatterjee SK
    Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.
    Quaglino E; Mastini C; Forni G; Cavallo F
    Curr Protoc Immunol; 2008 Aug; Chapter 20():Unit 20.9.1-20.9-10. PubMed ID: 18729063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.